Pharvaris (PHVS) Stock Price, Quote, News & History | Benzinga

Pharvaris NV (PHVS) Stock Price, Quote, News & History

PHVSNASDAQ

Trade with Public

Trade with Public

$35.80

0.481.36%

Last update: Aug 31, 5:25 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$35.31

Close

-

Volume / Avg.

156.98K / 508.85K

Day Range

$34.13 - $35.73

52 Wk Range

20.65 - 38.13

Market Cap

$2.50B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

3.09%

Days to Cover

2.78

Recent Pharvaris N.V. News

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to the stock, says Guggenheim analyst.

Priya Nigam

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.

Vandana Singh

This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

Vandana Singh

Gold Moves Higher; Campbell Soup Earnings Top Expectations

U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-155.19M

Investing Cash Flow (TTM)

-99.26K

Financing Cash Flow (TTM)

266.52M

Free Cash Flow (TTM)

-155.29M

Capital Expenditure (TTM)

-99.26K

Net Change in Cash (TTM)

111.23M

Analyst Trends and Forecast

0

0

0

0

May

1

Jun

1

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.11B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.08

Earnings Yield % (TTM)

-8.57%

Earnings Yield % (FWD)

-9.33%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.99

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$214.76K

Total Cash

$318.28M

Debt to Equity

0.00

Issuance of Debt (TTM)

-$214.76K

Repayment of Debt (TTM)

-$214.76K

Key Statistics

Open

$35.31

Close

-

Volume / Avg.

156.98K / 508.85K

Day Range

$34.13 - $35.73

52 Wk Range

20.65 - 38.13

Market Cap

$2.50B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

3.09%

Days to Cover

2.78

About

Sector

Health Care

Industry

Pharmaceuticals

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules,...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Pharvaris (PHVS) stock?

A

You can purchase shares of Pharvaris (NASDAQ:PHVS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Pharvaris (PHVS) competitors?

A

Other companies in Pharvaris’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Pharvaris (PHVS) stock?

A

Pharvaris has a consensus price target of $46.19.

Q

What is the current price for Pharvaris (PHVS)?

A

The stock price for Pharvaris (NASDAQ: PHVS) is $35.8 last updated August 31, 2026 at 5:25 AM EDT.

Q

Does Pharvaris (PHVS) pay a dividend?

A

There are no upcoming dividends for Pharvaris.

Q

When is Pharvaris (NASDAQ:PHVS) reporting earnings?

A

Pharvaris does not have any upcoming earnings scheduled.

Q

Is Pharvaris (PHVS) going to split?

A

There is no upcoming split for Pharvaris.

Q

What sector and industry does Pharvaris (PHVS) operate in?

A

Pharvaris is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.